Research on the Mechanism, Diagnosis, and Treatment of Very Early-Onset Inflammatory Bowel Disease Based on IL-10/IL-10RA Signaling Pathway Detection

Abstract

Very Early-Onset Inflammatory Bowel Disease (VEO-IBD) refers to inflammatory bowel disease with onset before the age of 6, exhibiting significant differences in clinical manifestations, genetic background, and treatment response compared to late-onset IBD. Research indicates that host monogenic defects play a key role in the pathogenesis of VEO-IBD, with mutations in IL-10 and its receptor (IL-10R) genes being particularly important. This article systematically elaborates on the pathogenic mechanisms, clinical features, diagnostic strategies, and therapeutic advancements related to the IL-10/IL-10RA signaling pathway, aiming to provide a theoretical basis for the development and application of relevant detection kits.

I. Overview and Genetic Background of VEO-IBD

VEO-IBD accounts for 5%–15% of pediatric IBD cases, with an incidence rate of approximately 4.37 per 100,000. Affected children exhibit characteristics such as early onset, strong familial clustering, and poor response to conventional treatments. To date, over 50 genes have been confirmed to be associated with VEO-IBD, among which mutations in IL-10, IL-10RA, and IL-10RB genes are prominent in the pathogenesis, serving as important genetic factors for severe intestinal inflammation in infants and young children.

II. IL-10/IL-10RA Signaling Pathway and Pathogenesis

IL-10 plays a central role in suppressing excessive immune responses and maintaining mucosal homeostasis by binding to its receptor. IL-10R consists of IL-10RA and IL-10RB subunits, and functional loss of the receptor leads to impaired downstream STAT3 phosphorylation and disrupted anti-inflammatory signal transduction, resulting in progressive intestinal inflammation (Figure 1). Homozygous mutations in IL-10 or IL-10RA/IL-10RB significantly enhance clinical phenotypes, confirming that defects in this pathway are a crucial molecular basis for VEO-IBD.

III. Clinical Manifestations and Endoscopic/Pathological Features

VEO-IBD caused by IL-10/IL-10RA gene mutations often presents with early-onset, refractory diarrhea, abdominal pain, bloody stools, and growth retardation. Perianal lesions are prominent, manifesting as multiple anal fissures, abscesses, or fistulas. Endoscopy reveals widespread skip ulcers and cobblestone-like changes in the colon (Figure 2). Histopathology is characterized by crypt abscesses, intraepithelial granulomas, and dense mononuclear cell infiltration (Figure 3). Some patients exhibit extraintestinal manifestations such as recurrent infections, folliculitis, or eczema (Figure 4), indicating systemic immune dysregulation.

IV. Diagnostic Strategies and Application of Genetic Testing

Diagnosis of VEO-IBD requires integrating clinical, endoscopic, pathological, and genetic evidence. For children with onset before age 6, severe disease, significant perianal lesions, poor treatment response, or a family history, monogenic mutations should be highly suspected. Genetic testing for IL-10/IL-10RA and related genes can identify pathogenic mutations, providing a basis for precise classification and treatment.

V. Current Treatments and Transplant Interventions

Conventional anti-inflammatory and immunosuppressive therapies have limited efficacy in children with IL-10 pathway defects. Nutritional support and surgical interventions may temporarily alleviate symptoms but often come with healing difficulties and recurrence risks. Currently, allogeneic hematopoietic stem cell transplantation has been shown to induce clinical remission in some children with IL-10/IL-10RA gene mutations, offering a potential cure.

VI. Prognosis and Future Perspectives

Children with VEO-IBD associated with IL-10/IL-10RA gene mutations have a poor prognosis. Early genetic diagnosis and timely transplant interventions are key to improving outcomes. Further development of kits for detecting IL-10/IL-10RA pathway functionality will facilitate early screening, precise diagnosis, and treatment monitoring, advancing the field toward personalized medicine.

VII. Which Manufacturers Provide IL10/IL10RA Kits?

Nanjing UA-Bio Biotechnology Co., Ltd. (UA-Bio) has independently developed the "Human IL10/IL10RA Binding Kit", a high-sensitivity in vitro detection platform specifically designed for studying the IL-10 signaling pathway—a critical pathway in immune regulation. This kit enables researchers to accurately and efficiently quantify the specific binding between interleukin-10 (IL-10) and its receptor IL-10RA, providing a stable and reliable standardized tool for mechanistic research and drug development in fields such as autoimmune diseases, inflammation regulation, and tumor immune microenvironments.

Nanjing UA-Bio Biotechnology Co., Ltd. is committed to providing innovative, high-quality core reagents and tools for immunology, inflammation research, and biopharmaceutical development. For detailed technical parameters, validation data, or specific application inquiries regarding the "Human IL10/IL10RA Binding Kit" (Catalog No.: UA086016), please feel free to contact us.